With this drug, the virus can’t spread because of the block in its replication.
It is possible that Trump’s embrace of this drug is based on a “political calculation,” according to an article from the Daily Beast :
“Trump did not support the development of more potent anti-viral drugs for children because of concerns, including possible political and moral concerns, that they might be seen as supporting the drug cartels or their sale in the United States,” said a statement.
The anti-viral drug has the potential to be a powerful enabler for the President’s plan to roll back an Obama administration initiative to address the epidemic in the United States , the Daily Beast story says. Although the Daily Beast story notes that the U.S. military and scientists who developed the drug in the last decade were “critical elements of the Obama effort,” no such effort exists under President Trump. The Trump team cited the current controversy on the anti-viral drug in arguing in the statement that the current ban on its use could lead to a spike in illegal usage.
“We believe the additional work to develop new anti-viral drugs is a strategic priority,” the statement read.
The Daily Beast article, which was first published on April 29, does note that the Department of Health and Human Services and the Department of Commerce have been working to strengthen a previously approved research contract to assess whether the new drug could help prevent coronavirus in the United States.
The Trump administration has made several remarks as of late about the need for this kind of drug, most notably on Monday, April 29, when he told a crowd at a West Virginia campaign rally, “We need drugs, but we don’t need to be taking them from other countries, when countries don’t provide those drugs at all.”
Since Trump took office, the administration has also taken steps to weaken regulations on drug approvals, even though it is very well established that these regulations are intended to prevent price increases and to boost pharmaceutical innovation and competition.
One of the more notable developments after President Trump took office, according to press reports, was the administration’s decision to withdraw the use of the Ebola “swine flu” vaccine, which had been approved for use in Europe. As the New York Times reports ,
The White House withdrew this spring, citing an increase in public concerns in the United States over the vaccine. The administration’s stance seemed to be a reflection of a political dynamic with two very competing views on the best response to an emerging virus: to try to keep it in Afghanistan and give it to Americans, or to try to keep it out of America’s territory and let it spread from there.